Dr. Surapaneni'S Genomic Solutions Profile
Key Indicators
- Authorised Capital ₹ 10.00 Cr
as on 31-01-2024
- Paid Up Capital ₹ 9.31 Cr
as on 31-01-2024
- Company Age 20 Year, 10 Months
- Last Filing with ROC 31 Mar 2018
- Revenue %
(FY 2017)
- Profit 99.99%
(FY 2017)
- Ebitda 99.99%
(FY 2017)
- Net Worth -100.38%
(FY 2017)
- Total Assets %
(FY 2017)
About Dr. Surapaneni'S Genomic Solutions
- CIN/LLPIN
U73100TG2004PTC042734
- Company No.
042734
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
25 Feb 2004
- Date of AGM
29 Sep 2018
- Date of Balance Sheet
31 Mar 2018
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Dr. Surapaneni'S Genomic Solutions?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Krishna Surapaneni  | Director | 25-Feb-2004 | Current |
Surapaneni Vimaladevi  | Director | 05-Feb-2019 | Current |
Financial Performance of Dr. Surapaneni'S Genomic Solutions.
Dr. Surapaneni'S Genomic Solutions Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 99.99% increase in profit. The company's net worth observed a substantial decline by a decrease of 100.38%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dr. Surapaneni'S Genomic Solutions?
In 2017, Dr. Surapaneni'S Genomic Solutions had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Imperium Software Technologies Private LimitedActive 13 years 8 monthsKrishna Surapaneni and Surapaneni Vimaladevi are mutual person
Decision Support Systems India LimitedActive 24 years 7 monthsSurapaneni Vimaladevi is a mutual person
Sushruta Medical Aid And Research Hospital LimitedActive 42 years 6 monthsKrishna Surapaneni and Surapaneni Vimaladevi are mutual person
- Medwrite It Solutions Private LimitedActive 17 years 7 months
Krishna Surapaneni and Surapaneni Vimaladevi are mutual person
- Medwrite India Software Solutions Private LimitedActive 20 years 11 months
Krishna Surapaneni and Surapaneni Vimaladevi are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Dr. Surapaneni'S Genomic Solutions?
Unlock and access historical data on people associated with Dr. Surapaneni'S Genomic Solutions, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dr. Surapaneni'S Genomic Solutions, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dr. Surapaneni'S Genomic Solutions's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
